Sun Pharma's growth prospects look healthy; analysts positive on the stock

Majority of analysts positive on the stock; their average target price indicates an upside potential of 15 per cent

Sun Pharmaceutical

Devangshu Datta

Listen to This Article

Sun Pharmaceutical Industries (Sun Pharma) reported a turnaround in the January-March quarter of the 2022-23 financial year (Q4FY23), declaring a profit after tax (PAT) of Rs 1,984 crore versus a

Also Read

Sun Pharma Q3 net profit up 5.2% as sales grow in India, US markets

India business to boost pharma, after US sales prove to be a mixed bag

Sun Pharma Q4: Consolidated net profit at Rs 1,984 crore, revenue up 15%

From Adani Wilmar to Havells India: Q4 results to watch out for today

Mankind Pharma IPO to open next week: Check price band, GMP, other details

NTPC in a sweet spot; likely to be poised for leadership in renewables

FMCG stocks get a boost from improving prospects; analysts are bullish

Improving prospects drive auto major Maruti Suzuki India's shares

IT stocks witness fresh turbulence; posts biggest decline in nearly 2 mths

Heavyweights lift benchmarks; Sensex less than 1% away from all-time high

First Published: Jun 9 2023 | 9:44 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to